NCT04627376 Multimodal Program for Cancer Related Cachexia Prevention
| NCT ID | NCT04627376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cyprus University of Technology |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2020-09-24 |
| Primary Completion | 2023-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2020-09-24 with a primary completion date of 2023-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to evaluate the effectiveness of a multifactorial education and support program for the prevention of cancer-related cachexia syndrome, for patients and their family caregivers during anti-cancer treatment.
Eligibility Criteria
Inclusion Criteria: 1. 18 years old or older 2. Participants must be diagnosed with solid tumour (stomach, colorectal, pancreas, breast, lung) 3. Participants needing chemotherapy/immunotherapy/hormone therapy/target therapy 4. Participants must be normal or pre cachectic as defined by the guidelines 5. Read and understand Greek or English Exclusion Criteria: 1. Haematologic tumors 2. Parenteral Nutrition 3. ECOG Performance status \>2 or Karnofsky Performance Status \<60% 4. Participant who can not introduce a family caregiver 5. Participants in cachexia or refractory cachexia stage as defined by the guidelines below: * \>5% weight loss over the past 6 months (in absence of simple starvation); OR * BMI \<20 and any degree of weight loss \>2%; OR * Appendicular skeletal muscle index consistent with sarcopenia (whole body fat-free mass index without bone determined by bioelectrical impedance (men \<14.6 kg/m²; women \<11.4 kg/m²) and weight loss \>2% 6. Patients who use complementary therapies (ex-acupuncture)
Contact & Investigator
Andreas Charalambous, PhD
STUDY DIRECTOR
Cyprus University of Technology Department of Nursing
Frequently Asked Questions
Who can join the NCT04627376 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04627376 currently recruiting?
Yes, NCT04627376 is actively recruiting participants. Contact the research team at andreas.charalambous@cut.ac.cy for enrollment information.
Where is the NCT04627376 trial being conducted?
This trial is being conducted at Limassol, Cyprus.
Who is sponsoring the NCT04627376 clinical trial?
NCT04627376 is sponsored by Cyprus University of Technology. The principal investigator is Andreas Charalambous, PhD at Cyprus University of Technology Department of Nursing. The trial plans to enroll 60 participants.